We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
According to Japanese drug sector sources, the current round of consolidation
in the domestic industry is not simply a defensive measure, and for some firms
the process is becoming a means to pursue overseas opportunities.
Able Laboratories and InvaGen announced the signing of an exclusive Development
Agreement for generic pharmaceutical products utilizing InvaGen's expertise
in pharmaceutical development.
Rigel Pharmaceuticals announced that it has received two milestone payments
from Daiichi Pharmaceuticals Co., Ltd., as part of their collaboration to identify
a new type of oncology drug.
On May 9, 2005, the law firm of Kenneth B. Moll & Associates will file in
federal court in Chicago, Ill., the first class action lawsuit on behalf of
all Italian citizens who allegedly died or were seriously injured by the pain
medication Vioxx.
On May 6, Daiichi Suntory Pharma (DSP) and BioMarin Pharmaceutical of California
jointly announced that they have expanded the scope of their existing licensing
agreement for Biopten, DSP's proprietary tetrahydrobiopterin agent for inborn
errors of metabolism.
Pharmaniaga Bhd is viewing
its up-and-coming small volume injectables (SVI) plant as groundwork for the
company's future participation in the biotechnology industry.
State-owned Brazilian drug manufacturer Far-Manguinhos is to take
over production of two off-patent generic ARV drugs, Ritonavir and Saquinavir,
from local drugmaker Cristalia.
The National Physical Laboratory (NPL), the UK's standards laboratory,
has outlined a series of technical projects aimed at bringing biopharmaceuticals
to market more rapidly by cutting test times and costs.